For the Inventor, By the Inventor

Enter assignee name

East Setauket, NY, United States of America

Lixte Biotechnology, Inc.

USPTO Granted Patents = 27

% Expired Patents = 14.8

EPO Patents = 14

Forward Citations = 269

Loading Chart...

Loading Chart...

18 inventors (with patents filed for the assignee):

John S Kovach (26 out of 30 patents)

Francis Johnson (10 out of 30 patents)

Robert A Volkmann (5 out of 74 patents)

4. Anthony Marfat (5 out of 62 patents)

5. Mickey L Wells (3 out of 3 patents)

6. Manuel Mameli (2 out of 2 patents)

7. Salvatore Lecca (2 out of 2 patents)

8. Alan F List (1 out of 23 patents)

9. Zhengping Zhuang (1 out of 8 patents)

10. David A Sallman (1 out of 2 patents)

11. Jason J Piotrowski (1 out of 1 patent)

12. Dumitru Ionescu (1 out of 16 patents)

13. Sze Chun Winson Ho (1 out of 1 patent)

14. Herui Wang (1 out of 1 patent)

15. Rongze Lu (1 out of 1 patent)

27 patents: Sort by Forward Citations

1. 12343342 - Methods for treating soft tissue sarcoma (2025-07-01),

2. 12168008 - Oxabicycloheptanes for modulation of immune response (2024-12-17),

3. 11931354 - Formulations of oxabicycloheptanes and oxabicycloheptenes (2024-03-19),

4. 11866444 - Oxabicycloheptane prodrugs (2024-01-09),

5. 11236102 - Oxabicycloheptane prodrugs (2022-02-01),

6. 10668062 - Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes (2020-06-02),

7. 10618908 - Oxabicycloheptane prodrugs (2020-04-14),

8. 10532050 - Formulations of oxabicycloheptanes and oxabicycloheptenes (2020-01-14),

9. 10434100 - Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes (2019-10-08),

10. 10413541 - Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders (2019-09-17),

11. 10399993 - Oxabicycloheptanes and oxabicycloheptenes, their preparation and use (2019-09-03),

12. 10364252 - Oxabicycloheptane prodrugs (2019-07-30),

13. 10149847 - Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes (2018-12-11),

14. 10023587 - Oxabicycloheptanes and oxabicycloheptenes, their preparation and use (2018-07-17),

15. 9994584 - Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid (2018-06-12),

Lixte Biotechnology, Inc. is a clinical-stage drug discovery company developing innovative drugs for the treatment of human cancers. Their mission is to discover drugs that inhibit the signaling pathways critical to the growth and survival of cancer cells. Lixte combines cutting-edge molecular biology and computational chemistry approaches to screen for promising anti-cancer compounds, with a focus on targeting enzymes involved in tumor development and progression. Through rigorous research and development practices, Lixte aims to improve the lives of cancer patients by providing effective and personalized treatment options.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

27 Patents

#1 in East Setauket, NY

#742 in New York

#12,405 in US

#23,968 in the World

East Setauket, NY, United States of America

Lixte Biotechnology, Inc.

Forward Citations = 269

18 inventors:

John S Kovach (26 out of 30 patents)

Francis Johnson (10 out of 30 patents)

Robert A Volkmann (5 out of 74 patents)

4. Anthony Marfat (5 out of 62 patents)

5. Mickey L Wells (3 out of 3 patents)

Please report any incorrect information to [email protected]

Loading…